Fusion-VAC-XS15

N/A

Report date: 2024/07/11 20:00:08

Base Information

Drug NameFusion-VAC-XS15
Drug Alias NameDNAJB1-PRKACA fusion transcript-based peptide vaccine(University Hospital Tuebingen)
ClassificationVaccines > Development/production technology > Synthetic peptide vaccineVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsGlioblastomaRhabdomyosarcomaSarcoma, Synovial +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Hospital Tuebingen
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Hospital Tuebingen
Inactive CompaniesN/A
Active IndicationsGlioblastomaRhabdomyosarcomaSarcoma, Synovial +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A